Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression

// Haolong Li 1 , Ning Xie 1 , Martin E. Gleave 1 and Xuesen Dong 1 1 The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Canada Correspondence to: Xuesen Dong, email: // Keywords : topoisomerase II, catalytic inhibitor, androgen receptor, prostate cancer, castration resistant prostate cancer Received : April 13, 2015 Accepted : April 23, 2015 Published : May 12, 2015 Abstract Although the new generation of androgen receptor (AR) antagonists like enzalutamide (ENZ) prolong survival of metastatic castration-resistant prostate cancer (CRPC), AR-driven tumors eventually recur indicating that additional therapies are required to fully block AR function. Since DNA topoisomerase II (Topo II) was demonstrated to be essential for AR to initiate gene transcription, this study tested whether catalytic inhibitors of Topo II can block AR signaling and suppress ENZ-resistant CRPC growth. Using multiple prostate cancer cell lines, we showed that catalytic Topo II inhibitors, ICRF187 and ICRF193 inhibited transcription activities of the wild-type AR, mutant ARs (F876L and W741C) and the AR-V7 splice variant. ICRF187 and ICRF193 decreased AR recruitment to target promoters and reduced AR nuclear localization. Both ICRF187 and ICRF193 also inhibited cell proliferation and delayed cell cycling at the G2/M phase. ICRF187 inhibited tumor growth of castration-resistant LNCaP and 22RV1 xenografts as well as ENZ-resistant MR49F xenografts. We conclude that catalytic Topo II inhibitors can block AR signaling and inhibit tumor growth of CRPC xenografts, identifying a potential co-targeting approach using these inhibitors in combination with AR pathway inhibitors in CRPC.